Industry Symposium With ACPE Credit

Industry supported symposia are scientific programs developed for educational purposes. All symposia are in compliance with Accreditation Council for Pharmacy Education (ACPE) criteria for planning and implementation. Each provide 1.5 contact hours of ACPE credit. Meals or snack items may be provided at the start of each event. Room capacities at symposia are limited and entrance is granted on a first-come, first-served basis.

Sunday, April 22, 11:30 a.m.-1:15 p.m. (Lunch Provided)

Case Studies & Conundrums: Practical Management of Tardive Dyskinesia for Neurologic and Psychiatric Pharmacists

Psychiatric and neurologic pharmacists are actively involved in the care of patients with long-standing psychiatric illness, many of whom receive first and second-generation antipsychotic medications. Specialty neurologic and psychiatric pharmacists have been shown to assess abnormal movements at a skill level comparable to trained physicians and are ideally positioned to assist in the differentiation of extrapyramidal symptoms (EPS) and identify patients at risk of developing or having already developed tardive dyskinesia (TD). They also may guide optimal medication selection; assist with procurement of appropriate agents; oversee dosing, titration, and adjustments that may be needed due to drug interactions; and screen for adverse effects from treatments. Using case-based scenarios and interactive audience response technology, CPNP attendees will review new data with clinical experts to ensure they are current with their assessment techniques and knowledgeable about new treatment options. Learn more.

Faculty

	Steve Stoner, PharmD, BCPP (Chair/Moderator) Clinical Professor and Chair University of Missouri at Kansas City School of Pharmacy Kansas City, MO
	Jason P. Caplan, MD, FAPM St. Joseph’s Hospital and Medical Center Phoenix, Arizona
	Sabrina Livezey, PharmD Vanderbilt Specialty Pharmacy Services Vanderbilt University Medical Center Nashville, Tennessee

Learning Objectives

1. Differentiate extrapyramidal symptoms (EPS) of pseudoparkinsonism and dystonia from chronic movements considered to be tardive dyskinesia (TD).
2. Consider use of VMAT2 inhibitors for tardive dyskinesia in appropriate patients and appraise criteria for use and how treatment should best be initiated.
3. Explore the short and long-term efficacy and tolerability of tardive dyskinesia treatments.
4. Using case examples, evaluate best practices for dosing/titration of VMAT2 inhibitors, management of concomitant medications (including anticholinergic agents), anticipate potential adverse effects, and consider appropriate duration of therapy.

Agenda

• Welcome and Introductions, Pre-test
• Case Studies
• Post-test; Audience Q&A with Faculty

Continuing Education

In support of improving patient care, Creative Educational Concepts, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacy (ACPE)

This application-based activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy (NABP) CPE Monitor electronic CE tracking system.

Offered by

Creative Educational Concepts, Inc.

Supported by

Neurocrine

Monday, April 23, 3:45-5:30 p.m.

Improving Care Coordination in Schizophrenia Management

Devon Sherwood PharmD, BCPP
Assistant Professor
College of Pharmacy
University of New England
Portland, Maine

Clinical Psychopharmacology Specialist
Spring Harbor Hospital
Westbrook, Maine

Learning Objectives

1. Explain common barriers to treatment adherence due to the chronic, complex nature of schizophrenia.
2. Examine the consequences of nonadherence to treatment regimens and be able to evaluate at-risk patients.
3. Illustrate how new treatment options for schizophrenia can increase adherence and provide cost-effective outcomes.
4. Identify the role of the pharmacist in correct agent selection to increase treatment adherence in patients with schizophrenia.

Agenda

1. Introduction schizophrenia: pathogenesis, epidemiology, and quality of life
2. Diagnosing disease, determining severity and impact on quality of life
3. Management of schizophrenia
   1. Optimizing therapy
   2. Improving adherence
4. Role of the pharmacist

Continuing Education

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-18-031-L01-P. The activity is available for CE credit through April 23, 2018.  

Indivior

Tuesday, April 24, 7:00-8:30 a.m.

Examining the Pharmacokinetics and Pharmacodynamics of LAI Antipsychotics: How Best to Individualize Treatment

Long-acting injectable (LAI) formulations for schizophrenia are important alternatives to oral antipsychotics and have been shown to be effective at preventing relapse in a population known to have high rates of relapse and rehospitalization. Additionally, use of these agents earlier in the disease course has been shown to positively impact long-term prognosis. While current guidelines recognize LAI antipsychotics as a treatment option, their use is under-utilized. Many clinician, patient and care system barriers exist which limit effective and consistent use of LAIs in patients that may benefit from their use. Additionally, clinicians can find it a challenge to understand the pharmacokinetic and pharmacodynamic considerations of the individual agents and appropriately initiate and adjust LAI antipsychotic dosing for individual patients. Through didactic and case-based presentations, this symposium will present the most up-to-date science on the differences in available LAI antipsychotics and the necessary considerations to select the appropriate agent for each patient, thus improving outcomes.

Faculty

Alkermes